Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced that the independent Data Safety Monitoring Board (”DSMB”) recommended that QPI-1002 (I5NP) continue on to the next phase of clinical testing. This followed review of available safety data from two clinical trials for Quark’s siRNA QPI-1002, at doses up to 10 mg/kg, [...]

Stem Cell Therapeutics Corp. (”SCT” or the “Company”) (TSX VENTURE:SSS) announced today it has been advised by the Data Safety Monitoring Board (”DSMB”) that a regularly scheduled safety analysis has been completed and the DSMB has recommended the Phase IIb stroke trial to continue as per the protocol.

Novavax, Inc. (Nasdaq: NVAX) announced that enrollment has been completed in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country of Mexico. An independent data and safety monitoring board has reviewed preliminary safety data from the first half of this cohort and [...]

Enrollment has ended early in a large, multicenter clinical trial comparing two distinct resuscitation strategies delivered by emergency medical service (EMS) providers to increase blood flow during cardiac arrest. The study’s independent monitoring board and the National Heart, Lung, and Blood Institute (NHLBI), the lead sponsor of the study, stopped enrollment based on preliminary data [...]

R. Duncan Hite, M.D., director of medical intensive care at Wake Forest University Baptist Medical Center, has been named the new chief of the Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases at Wake Forest University School of Medicine. Now a professor of internal medicine, Hite joined the faculty in 1994 as an assistant [...]